These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31168828)

  • 1. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
    Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
    Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
    Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
    Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage.
    Yu L; Jiang M; Qu P; Wu Z; Sun P; Xi M; Qin Y; Liu X; Liao G; Lei X; Sun L; Zhang Y; Li Z; Chen W; Qiao YL
    Int J Cancer; 2018 Aug; 143(4):813-822. PubMed ID: 29524206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and age-wise distribution of Human Papillomavirus type 16/18 infections among hospital screened women of a peri-urban area in West Bengal: Impact of socio-demographic factors.
    Bhattacharya A; Sen S; Mandal P; Sharma Saha S; Sarkar S; Pathak OP; Biswas L; Roy J; Banerjee R; Roy Chowdhury R; Pal M; Mukherjee A; Sengupta S
    Cancer Epidemiol; 2018 Jun; 54():31-37. PubMed ID: 29571035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of high-grade cervical disease among women referred directly to colposcopy after a positive HPV screening test varies with age and cytology findings.
    Farnsworth A; Roberts JM; Garland SM; Crescini J; Kaldor JM; Machalek DA
    Int J Cancer; 2020 Dec; 147(11):3068-3074. PubMed ID: 32484236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
    Kares S; Veijalainen O; Kholová I; Tirkkonen M; Vuento R; Huhtala H; Tuimala V; Mäenpää J; Kujala P
    APMIS; 2019 Nov; 127(11):710-716. PubMed ID: 31403733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of high risk human papillomavirus infection with different cervical cytological features among women undergoing health examination at the National Cancer Institute, Thailand.
    Laowahutanont P; Karalak A; Wongsena M; Loonprom K; Pukcharoen P; Jamsri P; Sangrajrang S
    Asian Pac J Cancer Prev; 2014; 15(14):5879-82. PubMed ID: 25081717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of HPV16/18/45 DNA testing of cervical specimens as a triage testing in cervical cancer screening].
    Li J; Chen W; Kang LN; Chen F; Guo DP; Li BY; Qiao YL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Jun; 35(3):254-9. PubMed ID: 23827061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
    Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
    Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
    PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cervical cancer in women with ASCUS in the Brazilian Unified National Health System: cost-effectiveness of the molecular biology method for HPV detection.
    Nomelini RS; Guimarães PD; Candido PA; Campos AC; Michelin MA; Murta EF
    Cad Saude Publica; 2012 Nov; 28(11):2043-52. PubMed ID: 23147946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.
    Coldman AJ; Phillips N; van Niekerk D; Smith L; Krajden M; Cook D; Quinlan DJ; Ehlen T; Miller D; Stuart GC; Peacock S; Martin RE; Franco EL; Ogilvie G
    J Obstet Gynaecol Can; 2015 May; 37(5):412-420. PubMed ID: 26168101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.